• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Accuray’s CyberKnife goes head-to-head against Intuitive’s da Vinci robot

Accuray’s CyberKnife goes head-to-head against Intuitive’s da Vinci robot

April 26, 2012 By MassDevice staff

Accuray logo

Sunnyvale, Calif.-based Accuray (NSDQ:ARAY) aims to establish a new gold standard for treating early-stage prostate cancer, with a 1st-of-its-kind clinical trial pitting its CyberKnife radiosurgery device against competing therapies, including Intuitive Surgical’s (NSDQ:ISRG) da Vinci surgical robot.

"An increasing number of patients are attracted to treatment with the CyberKnife System due to its unique ability to precisely treat the prostate while avoiding surrounding healthy tissue and critical structures," president & CEO Euan Thomson said in prepared remarks.

"Accuray believes in taking the lead in supporting studies, such as the Pace study, that will generate clinical data to support the benefits of technical innovation and provide the highest level of comparative evidence for the benefit of prostate cancer patients worldwide," Thomson added.

Accuray’s new Prostate Advances in Comparative Evidence study plans to follow more than 1,000 patients across 30 to 40 centers globally for up to 5 years after treatment.

Patients will receive either treatment with the CyberKnife system, surgical prostatectomy with the da Vinci robot, manual laparoscopic prostatectomy or conventionally fractionated intensity modulated radiation therapy.

Researchers will measure erectile function preservation, urinary and rectal toxicity, urinary incontinence and other common post-treatment side effects, according to a press release.

The news follows a new study finding that robot-assisted radical prostatectomy has cornered the market on treatment for localized prostate cancer.

"Contemporary data from the United States demonstrate that robot-assisted radical prostatectomy has supplanted open radical prostatectomy as the most common surgical approach for prostate cancer," according to the study’s authors. "Adjusted analyses demonstrate superior perioperative outcomes after robot-assisted radical prostatectomy in virtually all of the examined outcomes," when compared with open radical prostatectomy.

The CyberKnife radiosurgery system uses precisely targeted, massive doses of X-ray radiation to non-invasively destroy tumors.*

ARAY shares took a hit today, trading 3% lower to $7.67 as of about 12:15 p.m. today.

Correction, April 27, 11:00 a.m.: This article mistakenly stated that Accuray acquired the CyberKnife technology through the acquisition of TomoTherapy. The CyberKnife system was originally Accuray’s technology.

Filed Under: News Well, Oncology, Radiosurgery/Radiation therapy, Surgical Robotics, Wall Street Beat Tagged With: Accuray Inc., Clinical Trials, Intuitive Surgical, Prostate

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy